Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations
Copies of these presentations obtained through the QR code are for personal use only and may not be used without permission from AAIC and the authors of this presentation.
